Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.43 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.43 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.43 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2224793 | 0.93 | CYP3A4 (0.47) | CYP3A4CYP2D6HRH1KCNH2DRD2 | |
| SCHEMBL2222683 | 0.85 | CYP3A4 (0.44) | CYP3A4CYP2D6HRH1KCNH2DRD2 | |
| Cadaverine Tartrate SCHEMBL2222418 | 0.85 | MAPT (0.48) | CYP3A4CYP2D6HRH1KCNH2DRD2 | |
| Hydrochloric Acid SCHEMBL2224877 | 0.84 | CYP3A4 (0.43) | CYP3A4CYP2D6HRH1KCNH2DRD2 | |
| SCHEMBL2226483 | 0.83 | KCNH2 (0.47) | CYP3A4CYP2D6HRH1KCNH2DRD2 | |
| SCHEMBL14354338 | 0.82 | CYP3A4 (0.58) | CYP3A4CYP2D6HRH1KCNH2DRD2 | |
| SCHEMBL2224015 | 0.81 | CYP3A4 (0.41) | CYP3A4CYP2D6HRH1KCNH2DRD2 | |
| SCHEMBL2224629 | 0.79 | CYP3A4 (0.47) | CYP3A4CYP2D6HRH1KCNH2DRD2 | |
| SCHEMBL16986603 | 0.78 | POLB (0.44) | KCNH2HTR2AHTR2CHTR7POLB | |
| SCHEMBL2223411 | 0.77 | KCNH2 (0.49) | CYP3A4CYP2D6HRH1KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005709-A1 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-01-03 | — | — | US | claimed |
| EP-2521714-A1 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2012-11-14 | — | — | EP | claimed |
| WO-2011083487-A1 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-07-14 | — | — | WO | claimed |
| EP-2521714-B1 | Aromatic sulfone compounds useful in the treatment of central nervous disorders | SUVEN LIFE SCIENCES LTD (IN) | 2015-08-12 | — | — | EP | disclosed |
| US-9018231-B2 | Sulfone compounds as 5-HT6 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-04-28 | — | — | US | disclosed |
| US-20130005709-A1 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-01-03 | — | — | US | disclosed |
| EP-2521714-A1 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011083487-A1 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005709-A1 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | HTR6, HTR5A, HTR1A | HRH1 735/4885SLC6A2 34/4885HTR2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.